In breast cancer, acetylcholine activates muscarinic receptors on tumor-infiltrating lymphocytes to reduce their expression of PD-1 (also known as PDCD1) in vivo, leading to suppressed tumor growth due to the removal of the immune checkpoint and consequent increase in the anti-tumor immune response (Kamiya et al., 2019). The gene discussed is PDCD1; the disease is breast cancer.